Literature DB >> 15758838

Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients.

Pilar Brito-Zerón1, Manuel Ramos-Casals, Norma Nardi, Ricard Cervera, Jordi Yagüe, Miguel Ingelmo, Josep Font.   

Abstract

We conducted the current study to analyze the prevalence and clinical significance of circulating monoclonal immunoglobulins in patients with Sjögren syndrome (SS), focusing on the association with extraglandular features, immunologic markers, hematologic neoplasia, and hepatitis C virus (HCV) infection. We performed serum immunoelectrophoresis in 200 patients with primary SS and 37 patients with HCV-related SS. All patients fulfilled 4 or more of the 1993 European classification criteria for SS.Of the 200 patients with primary SS, 35 (18%) presented circulating monoclonal immunoglobulins. The monoclonal bands identified were 20 IgG (13 kappa, 7 lambda), 10 IgM (5 kappa, 5 lambda), 2 IgAkappa, and 3 free circulating light chains. Of the 37 SS-HCV patients, 16 (43%) had circulating monoclonal immunoglobulins. The monoclonal bands identified were 10 IgMkappa, 5 IgGlambda, and 1 free light lambda chain. Compared with primary SS patients, SS-HCV patients presented a higher frequency of monoclonal immunoglobulins (43% vs 18%, p = 0.001), with monoclonal IgMkappa being the most frequent monoclonal band. Six (12%) of the 51 SS patients with circulating monoclonal immunoglobulins presented hematologic neoplasia, compared with 3 (1.6%) of those without monoclonal immunoglobulins (p = 0.004; odds ratio = 8.13; 95% confidence intervals, 1.64-51.54). In 2 of the 6 patients with monoclonal immunoglobulins and lymphoproliferative disorders, a change of the monoclonal component was detected in previous immunoelectrophoresis determinations before the development of hematologic neoplasia. Circulating monoclonal immunoglobulins were detected in nearly 20% of patients with primary SS, with monoclonal IgG being the most frequent type of immunoglobulin detected. In SS-HCV patients, the prevalence of monoclonal immunoglobulins was higher (43%), with monoclonal IgM being the most frequent type found. SS-HCV patients presented a more restrictive monoclonal expression (limited to either monoclonal IgMkappa or monoclonal IgGlambda) than primary SS patients, who showed all types of heavy and light chains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15758838     DOI: 10.1097/01.md.0000157398.37679.47

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  9 in total

1.  Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.

Authors:  J-E Gottenberg; F Aucouturier; J Goetz; C Sordet; I Jahn; M Busson; J-M Cayuela; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

2.  Monoclonal gammopathy in rheumatic diseases.

Authors:  Yue Yang; Long Chen; Yuan Jia; Yang Liu; Lei Wen; Yaoxian Liang; Yuan An; Shi Chen; Yin Su; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-03-13       Impact factor: 2.980

Review 3.  Contributions of Major Cell Populations to Sjögren's Syndrome.

Authors:  Richard Witas; Shivai Gupta; Cuong Q Nguyen
Journal:  J Clin Med       Date:  2020-09-22       Impact factor: 4.241

Review 4.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

5.  MALT lymphoma of the thymus with Sjögren's syndrome: biphasic changes in serological abnormalities over a 4-year period following thymectomy.

Authors:  Takashi Sakamoto; Kouhei Yamashita; Chisaki Mizumoto; Maki Ueda; Tomoharu Takeoka; Terutoshi Hishita; Shigefusa Hada; Tatsuharu Ohno
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

6.  Isolation, characterization, and molecular modeling of a rheumatoid factor from a Hepatitis C virus infected patient with Sjögren's syndrome.

Authors:  Yu-Ching Lee; Keng-Chang Tsai; Sy-Jye Leu; Tuan-Jen Wang; Chia-Yu Liu; Yi-Yuan Yang
Journal:  ScientificWorldJournal       Date:  2013-12-30

Review 7.  B cell dysregulation in primary Sjögren's syndrome: A review.

Authors:  Hazim Mahmoud Ibrahem
Journal:  Jpn Dent Sci Rev       Date:  2019-10-21

Review 8.  Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature.

Authors:  Ioanna E Stergiou; Aikaterini Poulaki; Michael Voulgarelis
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

Review 9.  Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Alexei Shimanovsky; Juliana Alvarez Argote; Shruti Murali; Constantin A Dasanu
Journal:  BBA Clin       Date:  2016-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.